Navigation Links
Sinovac Announces Exercise of Over-Allotment Option
Date:2/1/2010

BEIJING, Feb. 1 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, announced today that the underwriters of its previously announced public common share offering have exercised in full their option to purchase an additional 1,500,000 common shares to cover over-allotments in the offering. As a result, Sinovac will issue and sell a total of 11,500,000 common shares at $5.75 per common share in this offering, including the 1,500,000 common shares pursuant to the exercise of the over-allotment option. Sinovac expects issuance and delivery of all 11,500,000 common shares to occur on February 2, 2010, subject to customary closing conditions.

Sinovac will receive net proceeds of approximately $62.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

UBS Securities LLC and Piper Jaffray & Co. are serving as joint bookrunners for the offering.

The offering is being made under Sinovac's currently effective shelf registration statements on Form F-3 filed with the Securities and Exchange Commission on November 18, 2009 and January 27, 2010. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, securities, and does not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained from UBS Securities LLC, Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171, U.S.A., telephone: 888-827-7275, or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, Suite 800, Minneapolis MN 55402, U.S.A., telephone: 1-800-754-4781.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and Panflu.1(TM), Sinovac's pandemic influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for a number of different infectious diseases including enterovirus 71, pneumococcal disease, Japanese encephalitis, haemophilus influenzae type b (Hib), meningitis, rabies, chickenpox, mumps and rubella. Sinovac is also conducting field trials for independently developed inactivated animal rabies vaccine.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law.

    For further information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x 9871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
     Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7033
     Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government
2. Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea
3. Sinovacs H1N1 Vaccine Passes Experts Evaluation Organized by SFDA
4. Sinovac Wins Beijing Public Health Bureaus Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
5. Sinovac Reports Unaudited Second Quarter 2009 Financial Results
6. Sinovac Schedules 2008 Annual General Meeting
7. Sinovac Reports Unaudited First Quarter 2009 Financial Results
8. Sinovac Announces that Government Investigation Rules Out Healives Role in Childs Death
9. Sinovac Provides Support to Chinas Ministry of Health to Aid Earthquake Victims
10. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
11. Rapport International Announces Partnership with SDL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her ... 9--24, 2017. This sacred and spiritual journey during the Summer Solstice will ...
(Date:3/24/2017)... PA (PRWEB) , ... March 24, 2017 , ... ... Oncology Nursing Society (ONS) wanted to create a communications platform that positions them ... this goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh ...
(Date:3/24/2017)... ... 24, 2017 , ... On June 9, 2017, Cassie Springer ... seminar in Chicago, Illinois. She will present on: , Filing Benefit Claims—Responding ... ERISA involve claims for long-term disability benefits. This session will address the ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate themselves on ... cultural practices, goods, services, and societal issues tend to appreciate and love the "Informed" ... practice of utilizing running events for causes around the world. , Running ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, ... their training and leads programs. , In February, 2017, Empower Brokerage introduced their ... Performance Partners is designed to teach how to maximize their sales efforts, as ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , Latin ... provided for the period 2015 through 2022. Also, a six-year historic analysis ...
(Date:3/24/2017)... BOTHELL, Wash. , March 23, 2017 /PRNewswire/ ... developer of advanced medical technology for non-invasive surgery, ... the Mirabilis System for treatment of uterine fibroids ... that it had received approval from the US ... study of the Mirabilis System in the United ...
(Date:3/23/2017)... Mar 23, 2017 Research and Markets has ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... 6.9% over the next decade to reach approximately $3.5 billion by ... forecasts for all the given segments on global as well as ...
Breaking Medicine Technology: